Miltenyi Biotec, Inc.
2303 Lindbergh St.
Tel: (530) 888-8871
About Miltenyi Biotec, Inc.
Miltenyi Biotec is a global leader in the design, development, manufacture, and integration of products that empower the advancement of biomedical research and enable cutting-edge cell and gene therapy. Starting with our proprietary magnetic-activated cell sorting (MACS) Technology, Miltenyi provides an innovative portfolio of cellular technologies that can be seamlessly used in a variety of research, translational, and clinical applications.
Our mission is to make cancer history. At Miltenyi Biotec, engineers, scientists, software developers, and many other professionals work together to improve human health by providing smarter cellular technology solutions to researchers and clinicians.
Miltenyi Biotec develops highly sophisticated tools for biomedical research and cellular therapy.
We’re proud to say that our products help customers and patients worldwide to make valuable progress in the fight against cancer.
And we know that our success depends on a complete range of skilled people – not only scientists but also technical engineers, corporate functions and sales and marketing professionals.
17 articles with Miltenyi Biotec, Inc.
Cellenion and Miltenyi Biotec Sign Co-Marketing Agreement to Provide a Time and Cost-Efficient Solution for the Development of Monoclonal Cell Lines
SCIENION AG and Miltenyi Biotec GmbH today announced that Scienion’s affiliate Cellenion and Miltenyi Biotec have signed a co-marketing agreement.
Lentigen Technology, A Miltenyi Biotec Company, Acquires University of Maryland, Baltimore CAR-T Cell Start-Up, Living Pharma
Miltenyi Biotec, Inc. And Cesca Therapeutics' Subsidiary Totipotentrx Announce Multi-Year Commercial Agreement For Bone Marrow Transplantation
Miltenyi Biotec, Inc. Receives FDA Approval For Clinimacs® CD34 Reagent System For Prevention Of Graft-Versus-Host Disease In The Treatment Of Acute Myeloid Leukemia
Miltenyi Biotec, Inc. Partners With Terso Solutions, Inc. for a Fully Automated, On-Site Inventory Management Program
Miltenyi Biotec, Inc.: Heart Disease and Cellular Therapy: Start of Phase III Clinical Trial "PERFECT" Using Autologous CD133+ Bone Marrow Stem Cells
Miltenyi Biotec, Inc.'s Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings
Miltenyi Biotec, Inc. Release: The New MACSQuant(TM) Analyzer Combines Cell Enrichment and Flow Cytometry
Miltenyi Biotec, Inc. 2006 Frost & Sullivan European Life Sciences And Pharmaceuticals Product Innovation Of The Year Award
PLC Medical Systems And Miltenyi Biotec, Inc. Sponsor Presentation On Stem Cell Therapy In Cardiac Surgery